Petvivo Holdings Stock Price, News & Analysis

PetVivo Holdings (OTCQX: PETV) reported strong fiscal Q1 2026 results with revenue increasing 141% to $298,000, driven by product line expansion and distributor network growth. The company's national distributor sales surged 192% to $198,000, representing 67% of total revenues.

Key operational highlights include signing a distribution agreement with Eq Especialidades for Mexico market entry, partnerships with PiezoBioMembrane for biomaterial development, and Digital Landia for AI integration. The company also secured a $4.4 million private placement and uplisted to the OTCQX Best Market.

Financial metrics show a gross profit increase of 69% to $187,000, though operating loss improved 9% to $1.8 million. Cash position strengthened to $3.3 million, up from $228,000 in March 2025, while total liabilities decreased 39% to $3.1 million.

PetVivo Holdings (OTCQX: PETV), a biomedical company focused on innovative medical devices and therapeutics for equines and companion animals, has scheduled its fiscal first quarter 2026 earnings conference call for Thursday, August 14, 2025, at 5:00 p.m. ET.

The company will release its financial results for the quarter ended June 30, 2025, prior to the call. Management will host a presentation followed by a Q&A session. Investors can access the call via toll-free dial-in or webcast, with replay options available through the company's investor relations website.

PetVivo Holdings (OTCQX: PETV) has announced its upgrade from the OTCQB Venture Market to the OTCQX Best Market, marking a significant milestone for the biomedical device company. The OTCQX Market, which currently hosts 625 securities out of approximately 12,000 OTC securities, is designed for established companies meeting high financial standards and corporate governance requirements.

The company specializes in innovative medical devices for horses and companion animals, featuring two key products: Spryng with OsteoCushion Technology, an intra-articular injectable device for joint pain management, and PrecisePRP, an off-the-shelf platelet-rich plasma product containing 4 billion platelets per vial for veterinary use.

[ "Upgrade to OTCQX Best Market demonstrates meeting higher financial standards and corporate governance requirements", "Enhanced visibility and liquidity for investors through OTCQX trading", "Innovative product portfolio with Spryng and PrecisePRP targeting the veterinary medical device market" ]

PetVivo Holdings (OTCQB: PETV) reported preliminary unaudited financial results for fiscal year 2025, marking significant growth and operational achievements. The company's revenue increased 17% to $1.1 million, driven by the expansion of Spryng® with OsteoCushion™ Technology from equine to companion animal markets.

Key financial metrics include a 31% increase in distributor network sales to $958,000, representing 85% of total revenues. The company's gross profit rose 15% to $995,000 with an 87.8% margin. Operating loss decreased 24% to $8.1 million, while net loss improved 27% to $8 million. Cash position strengthened to $3.3 million as of June 30, 2025, following a $4.4 million equity financing.

Operational highlights include reaching over 1,000 veterinary clinics across all 50 states, strategic partnerships with Digital Landia for AI integration, and VetStem for PrecisePRP® commercialization. The company strengthened its leadership team with key appointments and expanded its distribution network by adding Vedco and Clipper Distributing, while also entering the international market through a Mexican distribution agreement.

PetVivo Holdings (OTCQB: PETV), a biomedical company focused on therapeutic medical devices for animals, has scheduled its fiscal fourth quarter and full year 2025 earnings conference call for Monday, June 30, 2025, at 5:00 p.m. ET.

The company will release its financial results for the period ended March 31, 2025, before the conference call. Management will host a presentation followed by a Q&A session. Investors can access the call through a toll-free dial-in number or webcast, with a replay available afterward through the company's investor relations website.

PetVivo Holdings (OTCQB: PETV) has successfully completed its $5 million Series B Convertible Preferred Stock offering with the final $1 million purchase option exercise. The Series B shares are priced at $1.00 per share with a 1:1 conversion ratio to common stock.

The funding will support the commercialization of two key products: SPRYNG®, an injectable veterinary device for joint pain management, and PrecisePRP®, an off-the-shelf platelet-rich plasma product for veterinary use. PrecisePRP® offers consistent dosing with 4 billion platelets per vial and eliminates the need for blood draws or centrifugation.

PetVivo Holdings (OTCQB: PETV) has received $3 million through a partial exercise of a purchase option related to their Series B Convertible Preferred Stock offering. This is part of a larger $5 million equity financing deal, with $4 million total received to date and $1 million remaining to be exercised by June 26, 2025. The Series B shares are priced at $1.00 each with a 1:1 conversion rate to common stock. The funds will support the commercialization of SPRYNG, an injectable veterinary device for joint pain management, and PrecisePRP, an off-the-shelf platelet-rich plasma product for veterinary use. SPRYNG uses OsteoCushion Technology to restore joint mechanics, while PrecisePRP provides a consistent dose of 4 billion platelets per vial without requiring blood draws or centrifugation.

PetVivo Holdings (PETV) has announced a strategic partnership with Commonwealth, the ownership group behind Kentucky Derby winner Mage and Dubai World Cup Champion Country Grammer. The collaboration focuses on implementing PetVivo's SPRYNG with OsteoCushion Technology and Precise PRP products into Commonwealth's thoroughbred care protocols. SPRYNG is an intra-articular device for joint health, while Precise PRP is a first-in-class platelet-rich plasma product for elite equine athletes. The partnership includes clinical implementation, co-branded content, and educational initiatives to promote joint wellness awareness. Commonwealth will integrate these technologies as both preventative and treatment solutions for their high-performance horses, aligning with HISA's new welfare protocols for horse safety.

Digital Landia and PetVivo Holdings (OTCQB: PETV) have announced the launch of an invite-only MVP (minimum viable product) of Agentic.Pet, an autonomous pet artificial intelligence ecosystem. The platform, officially launched on May 23, 2025, is entering a stress-testing and debugging phase with select early adopters.

The MVP includes AI agents for veterinary diagnostics, behavioral analysis, and nutritional advising. Upcoming enhancements will feature pet facial recognition and specialized AI agents for blood tests, urine analysis, and radiological imaging. Access is currently limited to pet industry professionals and tech enthusiasts through an invite code system available at www.agenticpet.io.